Adcendo
Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.
About
Adcendo ApS is a biopharmaceutical company focused on the development of first-and best-in-class antibody-drug conjugates (ADCs) for the treatment of cancers with high unmet medical need. The company is advancing a pipeline of novel ADCs designed to target specific cancer cells and deliver potent cytotoxic payloads, aiming to improve patient outcomes. Teams look it up for Biotechnology, Pharmaceuticals, Oncology.
Frequently asked
What does Adcendo do?
Adcendo is a Biotechnology company that offers Services. Teams look it up for Pharmaceuticals, Oncology, Drug Discovery. It is based in Copenhagen, Denmark and was founded in 2017. Public records show about 60 people and $272M raised. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has Adcendo raised?
Adcendo has raised a total of $272M in funding. The most recent round on record is Series C.
Where is Adcendo headquartered?
Adcendo is headquartered in Copenhagen, Denmark.
When was Adcendo founded?
Adcendo was founded in 2017.
What industry does Adcendo operate in?
Adcendo operates in Biotechnology, Pharmaceuticals, Oncology, Drug Discovery, Biotech.
How many employees does Adcendo have?
Adcendo has approximately 60 people on record.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.
Google PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.